Recombinant human EPO-Fc fusion proteins with prolonged...

Details Recombinant human EPO-Fc fusion proteins with prolonged... Recombinant human EPO-Fc fusion proteins with prolonged...

2006-01-27

2009-12-01

Fronda, Christian L (Department: 1652)

Drug, bio-affecting and body treating compositions

Conjugate or complex of monoclonal or polyclonal antibody,...

C530S350000, C530S391100

Reexamination Certificate

active

07625564

ABSTRACT:
A recombinant fusion protein comprising a human erythropoietin peptide portion linked to an immunoglobulin peptide portion is described. The fusion protein has a prolonged half-life in vivo in comparison to naturally occurring or recombinant native human erythropoietin. In one embodiment of the invention, the protein has a half-life in vivo at least three fold higher than native human erythropoietin. The fusion protein also exhibits enhanced erythropoietic bioactivity in comparison to native human erythropoietin. In one embodiment, the fusion protein comprises the complete peptide sequence of a human erythropoietin (EPO) molecule and the peptide sequence of an Fc fragment of human immunoglobulin IgG1. The Fc fragment in the fusion protein includes the hinge region, CH2 and CH3 domains of human immunoglobulin IgG1. The EPO molecule may be linked directly to the Fc fragment to avoid extraneous peptide linkers and lessen the risk of an immunogenic response when administered in vivo. In one embodiment the hinge region is a human Fc fragment variant having a non-cysteine residue at amino acid 6. The invention also relates to nucleic acid and amino acid sequences encoding the fusion protein and transfected cell lines and methods for producing the fusion protein. The invention further includes pharmaceutical compositions comprising the fusion protein and methods of using the fusion protein and/or the pharmaceutical compositions, for example to stimulate erythropoiesis in subjects in need of therapy.

REFERENCES:
patent: 5116964 (1992-05-01), Capon et al.
patent: 5618698 (1997-04-01), Lin
patent: 5908626 (1999-06-01), Chang et al.
patent: 5916773 (1999-06-01), Mele et al.
patent: 6096871 (2000-08-01), Presta et al.
patent: 6165476 (2000-12-01), Strom et al.
patent: 6403077 (2002-06-01), Strom et al.
patent: 6548653 (2003-04-01), Young et al.
patent: 6586398 (2003-07-01), Kinstler et al.
patent: 6660843 (2003-12-01), Feige et al.
patent: 6750334 (2004-06-01), Gray et al.
patent: 6797493 (2004-09-01), Sun et al.
patent: 6808902 (2004-10-01), Treuheit et al.
patent: 6900292 (2005-05-01), Sun et al.
patent: 6936439 (2005-08-01), Mann et al.
patent: 6987006 (2006-01-01), Fleer et al.
patent: 6989365 (2006-01-01), Fleer et al.
patent: 7030226 (2006-04-01), Sun et al.
patent: 7041478 (2006-05-01), Fleer et al.
patent: 7056701 (2006-06-01), Fleer et al.
patent: 2004/0063912 (2004-04-01), Blumberg et al.
patent: WO99/02709 (1999-01-01), None
patent: WO99/58662 (1999-11-01), None
patent: WO99/66054 (1999-12-01), None
patent: WO01/03737 (2001-01-01), None
patent: WO01/30320 (2001-05-01), None
patent: WO01/36489 (2001-05-01), None
patent: WO01/76640 (2001-10-01), None
patent: WO0181405 (2001-11-01), None
patent: WO02/48194 (2002-06-01), None
patent: WO03/046013 (2003-06-01), None
patent: WO03/048210 (2003-06-01), None
patent: WO2004004798 (2004-01-01), None
patent: WO2004/101739 (2004-11-01), None
patent: WO2005/001025 (2005-01-01), None
patent: WO2005001025 (2005-01-01), None
patent: WO2005/063808 (2005-07-01), None
patent: WO2005/079232 (2005-09-01), None
patent: 2006/079169 (2006-08-01), None
Chica et al. Curr Opin Biotechnol. Aug. 2005;16(4):378-84.
Sen et al. Appl Biochem Biotechnol. Dec. 2007;143(3):212-23.
Su L, Chen SS, Yang KG, Liu CZ, Zhang YL, Liang ZQ; High-level expression of human stem cell factor fused with erythropoietin mimetic peptide inEscherichia coli; Protein Expr Purif; Jun. 2006; 47(2):477-82; EpubNov. 28, 2005.
Lee DE, Son W, Ha BJ, Oh MS, Yoo OJ; The prolonged half-lives of new erythropoietin derivatives via peptide addition; Biochem Biophys Res Commun; Jan. 6, 2006;339(1):380-5; Epub Nov. 14, 2005.
Dumont JA, Bitonti AJ, Clark D, Evans S, Pickford M, Newman SP; Delivery of an erythropoietin-Fc fusion protein by inhalation in humans through an immunoglobulin transport pathway; J Aerosol Med.; 2005 Fall;18 (3):294-303.
Way JC, Lauder S, Brunkhorst B, Kong SM, Qi A, Webster G, Campbell I, McKenzie S, Lan Y, Marelli B, Nguyen LA, Degon S, Lo KM, Gillies SD; Improvement of Fc-erythropoietin structure and pharmacokinetics by modification at a disulfide bond; Protein Eng Des Sel; Mar. 2005;18(3):111-8; Epub Apr. 8, 2005.
Bitonti AJ, Dumont JA, Low SC, Peters RT, Kropp KE, Palombella VJ, Stattel JM, Lu Y, Tan CA, Song JJ, Garcia AM, Simister NE, Spiekermann GM, Lencer WI, Blumberg RS; Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway; Proc Natl Acad Sci USA; Jun. 29, 2004; 101(26):9763-8; Epub Jun. 21, 2004.
Dalle B, Henri A, Rouyer-Fessard P, Bettan M, Scherman D, Beuzard Y, Payen E.; Dimeric erythropoietin fusion protein with enhanced erythropoietic activity in vitro and in vivo; Blood; Jun. 15, 2001; 97 (12):3776-82.
Sytkowski AJ, Lunn ED, Risinger MA, Davis KL; An erythropoietin fusion protein comprised of identical repeating domains exhibits enhanced biological properties; J Biol Chem; Aug. 27, 1999; 274(35):24773-8.
Coscarella A, Liddi R, Bach S, Zappitelli S, Urso R, Mele A, De Santis R.; Pharmacokinetic and immunogenic behavior of three recombinant human GM-CSF-EPO hybrid proteins in cynomolgus monkeys; Mol Biotechnol; Oct. 1998; 10(2):115-22.
Amoresano A, Andolfo A, Siciliano RA, Mele A, Coscarella A, De Santis R, Mauro S, Pucci P, Marino G; Structural characterization and independent folding of a chimeric glycoprotein comprising granulocyte-macrophage colony stimulating factor and erythropoietin sequences; Glycobiology; Aug. 1998; 8(8): 779-90.
Coscarella A, Carloni C, Liddi R, Mauro S, Novelli S, Mele A, Masella B, Valtieri M, De Santis R.; Production of recombinant human GM-CSF-EPO hybrid proteins: in vitro biological characterization; Eur J Haematol; Oct. 1997; 59(4): 238-46.
Way, J.C. et al., Improvement of Fc-erythropoietin Structure and Pharmacokinetics by Modification at a Disulfide Bond, Protein Engineering, Design & Selection, Mar. 2005, vol. 18, No. 3, pp. 111-118.
Bitonti, A.J. et al., Pulmonary Delivery of an Erythropoietin Fc Fusion Protein in Non-human Primates Through an Immunoglbulin Transport Pathway, Proceedings of the National Academy of Sciences of the United States of America, Jun. 2004, vol. 101, No. 26, pp. 9763-9768.
Schriebl, K. et al., Biochemical Characterization of rhEpo-Fc Fusion Protein Expressed in CHO Cells, Protein Expression & Purification, Oct. 2006, vol. 49, No. 2, pp. 265-275.
Written Opinion issued by the Australian Patent Office on behalf of the Intellectual Property Office of Singapore on corresponding Singapore Patent Application No. SG 200805180-7, mailed Jun. 24, 2009.

Affiliated with

Also associated with

Rating

Recombinant human EPO-Fc fusion proteins with prolonged... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Recombinant human EPO-Fc fusion proteins with prolonged..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant human EPO-Fc fusion proteins with prolonged... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4148113